New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE51.9%−480.1%−126.2%−123.1%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 3.53× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA4.0×3.6×2.4×3.5×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

51.90% (480.07%) (126.19%) (123.08%)
ROA
(54.15%) (47.68%) (85.08%) (85.24%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(88.64%) (109.40%) (326.11%) (176.78%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(3.17) (2.31) (2.67) (2.15)
Free Cash Flow
(23.50) (21.67) (25.03) (27.15)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 17, 2026